Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But Johnson & Johnson ($JNJ) is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too--including lung cancer--and Thursday the companies announced a further $817 million deal. More